Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Oppel

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Physical Review Letters|February 2, 2013
Superresolving multiphoton interferences with independent light sourcesS Oppel, T Büttner, P Kok, et al.
Physical Review Letters|January 24, 2015
Directional superradiant emission from statistically independent incoherent nonclassical and classical sourcesS Oppel, R Wiegner, G S Agarwal, et al.
Spine|September 25, 2001
Five-year results from chemonucleolysis with chymopapain or collagenase: a prospective randomized studyR H Wittenberg, S Oppel, F A Rubenthaler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2008
Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumorsM Gajda, O Camara, S Oppel, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Physical Review Letters|February 2, 2013
Superresolving multiphoton interferences with independent light sourcesS Oppel, T Büttner, P Kok, et al.
Physical Review Letters|January 24, 2015
Directional superradiant emission from statistically independent incoherent nonclassical and classical sourcesS Oppel, R Wiegner, G S Agarwal, et al.
Spine|September 25, 2001
Five-year results from chemonucleolysis with chymopapain or collagenase: a prospective randomized studyR H Wittenberg, S Oppel, F A Rubenthaler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2008
Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumorsM Gajda, O Camara, S Oppel, et al.
Pageof 1